Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma
Open Access
- 8 April 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 115 (14), 2864-2871
- https://doi.org/10.1182/blood-2009-10-250555
Abstract
The anti-CD20 antibody rituximab has substantially improved outcomes in patients with B-cell non-Hodgkin lymphomas. However, many patients are not cuKeywords
This publication has 56 references indexed in Scilit:
- CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomasBlood, 2009
- Inhibitors of MyD88-Dependent Proinflammatory Cytokine Production Identified Utilizing a Novel RNA Interference Screening ApproachPLOS ONE, 2009
- Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell LymphomasJournal of Nuclear Medicine, 2009
- Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximabBlood, 2009
- Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II StudyJournal of Clinical Oncology, 2008
- New Treatment Options Have Changed the Survival of Patients With Follicular LymphomaJournal of Clinical Oncology, 2005
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- Meta-Analysis to Evaluate the Role of Interferon in Follicular LymphomaJournal of Clinical Oncology, 2005
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene, 2003
- Effect of interferon-α on CD20 antigen expression of B–cell chronic lymphocytic leukemiaCytokines, Cellular & Molecular Therapy, 2000